Skip to main content
Contact Us
Subscribe
E-Edition
58°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aptorum Group Limited
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
April 30, 2024
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
March 06, 2024
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
December 22, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
December 21, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
November 16, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
August 10, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
June 22, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris
June 09, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency
May 05, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited
May 01, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
March 27, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
March 03, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
March 03, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China
March 02, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency
February 10, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023
February 06, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Announces 1-for-10 Reverse Stock Split
January 20, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms
January 04, 2023
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders
December 22, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
December 16, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
December 09, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)
November 25, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency
November 18, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022
November 08, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022
September 30, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong
September 15, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics
September 15, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022
August 25, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022
May 17, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
May 02, 2022
From
Aptorum Group Limited
Via
Business Wire
Tickers
APM
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.